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1. Introduction 
Epilepsy is a neurological disorder that disrupts the normal transmission of electrical signals 
in the brain and is characterised by abnormal electrical neuronal activity resulting clinically 
in unprovoked recurring seizures. Partial-onset seizures are those that involve only a 
portion of the brain at seizure onset. The prevalence of epilepsy varies between 4 and 8 cases 
per 1,000 individuals in developed countries (Hauser, 1990), and partial seizures are the 
predominant type of epileptic seizures (Kotsopoulos et al., 2002).  
Epileptic seizures are associated with significant morbidity, impaired quality of life, 
mortality, and are a primary driver of hospital admissions and health care costs. A literature 
review reported an increased mortality risk for people with epilepsy as compared with the 
general population (Hitiris et al., 2007). A bottom-up, prevalence-based, cost-of-illness 
analysis estimated the costs of epilepsy from a societal perspective in the 25 European Union 
member countries, plus Iceland, Norway, and Switzerland (Pugliatti et al., 2007). The 
estimated total cost of the disease in Europe was € 15.5 billion in 2004, indirect costs related 
to productivity loss being the single most important cost category (€ 8.6 billion). The total 
cost per case was € 2,000–11,500 and the estimated cost per European individual was € 33. 
Treatment with anti-epileptic drugs (AEDs) is the mainstay of therapy for people with 
epilepsy and treatment tends to begin with monotherapy (Brodie & Dichter, 1997). First-
generation AEDs available before 1980 (e.g. carbamazepine, phenytoin, phenobarbital, 
valproic acid) are used first-line as monotherapy (Perucca & Meador, 2005). Although many 
patients respond to their first treatment, more than 1 in 3 patients have seizures despite 
treatment with AEDs (Schmidt & Gram, 1995). Treatment of refractory epilepsy will move to 
polytherapy by adding second-generation AEDs available after 1993 (e.g. felbamate, 
gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, tiagabine, topiramate, 
vigabatrin, zonisamide) to monotherapy regimens (adjunctive therapy). A literature review of 
systematic reviews reported that second-generation AEDs were effective as adjunctive therapy 
for refractory epilepsy as compared with placebo (Wilby et al., 2005). Also, a literature review 
of economic evaluations of second-generation AEDs showed that adjunctive therapy of 
refractory epilepsy with AEDs appears to be cost-effective (Simoens, 2010). 
Several factors inform the choice of the most appropriate treatment regimen in patients 
requiring adjunctive therapy. Of key importance is that adjunctive therapy for uncontrolled 
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epilepsy is effective in achieving seizure freedom or reduction in a group of patients who have 
continued to experience a high seizure burden despite initial treatment for their epilepsy. 
Given the chronic nature of epilepsy and the requirement for life-long management in many 
cases, it is important that treatments are tolerable. The ease of use and convenience of the drug 
also need to be considered. Key positive attributes are treatments that do not require multiple 
administrations a day and those with flexible dosing options. Clinical guidance also states that 
the AED treatment strategy should be individualized according to the seizure type, epilepsy 
syndrome, co-medication and co-morbidity, the individual’s lifestyle, and the preferences of 
the individual, their family and/or those who care for the patient as appropriate (National 
Institute for Health and Clinical Excellence, 2004). 
Lacosamide (Vimpat®, UCB Pharma, Brussels, Belgium) is a second-generation AED which 
is indicated as adjunctive therapy for partial-onset seizures with or without secondary 
generalisation in patients from 16 years of age in Europe (European Medicines Agency, 
2008). Lacosamide (R-2-acetamido-N-benzyl-3-methoxypropionamide) is a functionalised 
amino acid. Lacosamide is hypothesized to have a dual mode of action: it selectively 
enhances slow inactivation of voltage-gated sodium channels and binds to collapsin 
response mediator protein-2, a protein which is mainly expressed in the central nervous 
system.  
Trials in healthy adults have shown that lacosamide is rapidly absorbed and is 
predominantly excreted as unchanged lacosamide (Ben-Menachem, 2008). It has an oral 
bioavailability of approximately 100% and an elimination half-life of around 13 hours. 
Lacosamide has a low potential for pharmacokinetic interaction. The protein binding is 
low (<15%), thus reducing the potential for displacement interactions. Also, lacosamide 
does not influence the pharmacokinetic profile or plasma concentrations of commonly-
used AEDs such as carbamazepine or valproic acid. Pharmacokinetic parameters do not 
differ between genders or single or repeat dose administration (European Medicines 
Agency, 2008).   
Lacosamide is available in five formulations in Europe, an oral tablet (50 mg, 100 mg, 150 
mg and 200 mg) and a 15mg/ml syrup, and must be taken twice a day. The recommended 
starting dose is 50 mg twice a day which should be increased to an initial therapeutic dose of 
100 mg twice a day after one week. Depending on response and tolerability, the 
maintenance dose can be further increased by 50 mg twice a day every week, to a maximum 
daily dose of 400 mg (200 mg twice a day). The recommended daily dose for lacosamide is 
300 mg/day.  
The aim of this chapter is to conduct a health technology assessment of adjunctive therapy 
with lacosamide for partial-onset seizures in adult patients by means of a review of the 
international literature. The literature study focuses specifically on the safety, tolerability, 
efficacy, costs, cost-effectiveness and budget impact of lacosamide. The findings may serve 
to aid local decision-makers in allocating scarce health care resources and to inform the 
prescribing behavior of physicians. 
2. Methods 
2.1 Search strategy 
Studies were identified by searching PubMed, Centre for Reviews and Dissemination 
databases (Database of Abstracts of Reviews of Effects, National Health Service Economic 
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Evaluation Database, and Health Technology Assessments Database), Cochrane Database of 
Systematic Reviews, and EconLit from January 1999 to March 2011. Additionally, the 
bibliography of included studies was checked for other relevant studies. Search terms 
included ‘epilepsy’, ‘refractory epilepsy’, ‘partial-onset seizures’, ‘adjunctive therapy’, ‘add-
on therapy’, ‘anti-epileptic drugs’, ‘lacosamide’, ‘adult’, ‘safety’, ‘tolerability’, ‘efficacy’, 
‘effectiveness’, ‘pharmaco-economics’, ‘cost’, ‘cost analysis’, ‘economic evaluation’, ‘cost-
effectiveness’, ‘cost-minimisation’, ‘cost-consequence’, ‘cost-utility’, ‘cost-benefit’, ‘budget 
impact’ alone and in combination with each other. 
The literature search included articles published in peer-reviewed journals. Additionally, 
relevant congress abstracts were identified by searching the congress databases of the 
European Neurological Society, the American Academy of Neurology, and Outcomes 
Research Digest (an electronic database of abstracts presented at conferences of the 
International Society of Pharmacoeconomics and Outcomes Research). Finally, UCB Pharma 
was contacted for any unpublished studies. 
2.2 Selection criteria 
The literature review included clinical studies examining the safety, tolerability or efficacy 
of adjunctive therapy with lacosamide for partial-onset seizures in adult patients. The 
inclusion of clinical studies was restricted to randomized controlled trials or open-label 
extension trials. Other study designs (e.g. case studies) were not considered. Cost studies 
were included if they compared health care and/or other costs of lacosamide and an 
alternative treatment for partial-onset seizures. Evidence about cost-effectiveness was 
derived from economic evaluations. An economic evaluation was defined as a study 
comparing lacosamide with an alternative treatment in terms of both costs and 
consequences (Drummond et al., 2005) (see Figure 1). Economic evaluations were excluded 
if treatment of partial-onset seizures did not involve lacosamide or if studies analyzed a 
single intervention without a comparator.  
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Fig. 1. Economic evaluation of lacosamide 
A budget impact analysis explored how a change in the current mix of treatment strategies 
by the introduction of lacosamide would impact drug spending on partial-onset seizures 
(see Figure 2). 
Studies evaluating intravenous lacosamide were excluded because this article focuses on 
chronic adjunctive therapy. Literature reviews were searched for original studies, but were 
not included as such. The review was limited to studies published in English, French, Dutch, 
or German for practical reasons. 
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Fig. 2. Budget impact analysis of lacosamide 
3. Results 
3.1 Search results 
Few studies have focused on adjunctive therapy with lacosamide for partial-onset seizures 
in adult patients: the researcher identified 32 citations, but only nine studies were included 
in the review: three randomized controlled trials published in peer-reviewed journals14-16, 
three open-label extension studies published as abstracts (Ben-Menachem et al., 2009; 
Rosenfeld et al., 2009; Faught et al., 2010; Husain et al., 2010), one economic evaluation 
published in a peer-reviewed journal (Bolin et al., 2010), and two economic evaluations 
published as abstracts (one of which also included a budget impact analysis) (Simoens et al., 
2010; Soini et al., 2009). Studies were excluded because of one or more of the following 
reasons: disease other than refractory epilepsy; study not involving lacosamide; study of 
intravenous lacosamide; study of pharmacodynamic and/or pharmacokinetic profile of 
lacosamide; literature review rather than original study; case study.  
3.2 Safety, tolerability and efficacy 
Three randomised, multicentre, double-blind, placebo-controlled trials have been carried 
out on the efficacy of adjunctive therapy with lacosamide: phase IIb trial 667, phase III trial 
754 and phase III trial 755 (Ben-Menachem et al., 2007; Chung et al., 2010; Halasz et al., 
2009). The three trials were similar in design and patient baseline characteristics. 
All patients included in these pivotal trials were patients who had uncontrolled epilepsy 
despite previous treatment with at least two other AEDs (concurrently or sequentially) and 
who were actively treated with concomitant AEDs as standard therapy. The most 
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commonly used concomitant AEDs were carbamazepine, levetiracetam and lamotrigine. 
The primary objective of these trials was to evaluate the efficacy of lacosamide as adjunctive 
therapy following treatment failure with at least two other AEDs and co-administered with 
one or two other AEDs (trial 667) or up to three other AEDs (trials 754 and 755) in patients 
with uncontrolled partial-onset seizures. The secondary objective was to evaluate the safety 
of lacosamide. Patients were randomised to a 200 mg, 400 mg or 600 mg daily dose of 
lacosamide or placebo.  
Outcomes were measured in terms of the reduction in seizure frequency, 50% responder 
rate and seizure-free status. Responder rate was assessed as a reduction in partial-onset 
seizure frequency of at least 50% from baseline to maintenance phase. Seizure-free status 
was determined for patients who completed the maintenance phase with zero seizures. 
Improvements in quality of life, patient function and health status were assessed via 
secondary endpoints including the Quality of Life Inventory In Epilepsy (QOLIE-31) scale, 
the Seizure Severity Scale (SSS) and the Patient Global Impression of Change (PGIC) scale. 
Patients treated with lacosamide 400 mg/day and 600 mg/day in trial 667 showed a 
statistically significant reduction in seizure frequency at maintenance endpoint (after 18 
weeks) as compared with placebo (400 mg/day: p = 0.0023; 600 mg/day: p = 0.0084). 
Patients in trial 754 and 755 also displayed a statistically significant reduction in seizure 
frequency when treated with lacosamide as compared with patients treated with placebo 
(Trial 754: 400 mg/day p = 0.0078, 600 mg/day p = 0.0061; Trial 755: 200 mg/day p = 0.0223, 
400 mg/day p = 0.0325). Lacosamide was associated with a significantly greater median 
percent reduction in seizure frequency from baseline at a dose of 400 mg/day and 600 
mg/day across trials. In trial 755, lacosamide 200 mg/day was associated with a 
significantly greater median seizure reduction as compared with placebo (p = 0.04). 
Treatment with lacosamide (200–600 mg/day) gave higher responder rates as compared 
with treatment with placebo. The differences were generally significant as compared with 
placebo for patients treated with lacosamide 400 mg/day and lacosamide 600 mg/day.  
A pooled analysis of the trial data suggested that the median percent reduction in seizure 
frequency per 28 days from baseline to maintenance period amounted to 18.4% for placebo, 
33.3% for lacosamide 200 mg/day (p<0.01), 36.8% for 400 mg/day (p<0.001), and 39.4% for 
600 mg/day. The percentage of patients attaining a reduction in seizure frequency of at least 
50% was 22.6% with placebo, 34.1% with lacosamide 200 mg/day (p<0.05), 39.7% with 
lacosamide 400 mg/day (p<0.001), 39.6% with lacosamide 600 mg/day. The median percent 
reduction in seizure frequency and the percentage of patients attaining a reduction in 
seizure frequency of at least 50% did not vary depending on the number of previously used 
AEDs. Patient responders with more than 50% seizure reduction in the lacosamide 
treatment groups experienced significant improvements in QOLIE-31 and SSS scores as 
compared to baseline (p<0.05 for all comparisons of responders to non-responders) (Cramer 
et al., 2010). The largest improvements were gained for quality-of-life scores including the 
QOLIE-31 subscales ‘seizure worry’ and ‘social functioning’, as well as the SSS overall score. 
With respect to PGIC, more than 80% of lacosamide responders reported an improved 
health status. Finally, there seemed to be a dose-responsive trend for seizure freedom rates: 
2.7%, 3.3% and 4.8% for lacosamide 200, 400 or 600 mg/day as compared with 0.9% for 
placebo (French et al., 2009). 
The most common drug-associated treatment-emergent adverse events in the lacosamide 
treatment arms of the pivotal trials were dizziness and nausea (Gil-Nagel et al., 2009). 
Headache was also commonly reported with lacosamide. The incidence of adverse events 
was generally higher in the forced titration phase as compared with the maintenance phase, 
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indicating a reduction in these adverse events over time. Forced titration does not reflect 
usual clinical practice. Adverse events were reported to be of mild or moderate intensity. 
Three open-label extension studies of the pivotal trials explored the long-term safety, 
tolerability and efficacy of lacosamide (see Table 1) (Ben-Menachem et al., 2009; Rosenfeld et 
al., 2009; Faught et al., 2010; Husain et al., 2010). Long-term treatment with lacosamide 
produced a sustained efficacy in and was generally well tolerated by patients suffering from 
partial-onset seizures. The incidence of adverse events, as well as vital signs and clinical 
laboratory and ECG findings, among patients taking lacosamide were similar to those 
reported with short-term use (O’Brien, 2010). 
3.3 Costs 
No cost study comparing lacosamide with an alternative treatment for partial-onset seizures 
was identified in the literature. It is difficult to determine the cost implications of adjunctive 
therapy with lacosamide on patients, the health care system and society. Therefore, Table 1 
proposes the major items that need to be considered when calculating costs from a societal 
perspective. With respect to direct health care costs, current treatment strategies include 
pharmacotherapy with AEDs throughout life, surgery, and alternative measures — usually 
palliative — such as vagus nerve stimulation. A study also needs to consider the cost (and 
clinical) implications of the fact that AED therapy may affect co-morbid disease, that drugs 
used to treat co-morbid diseases may influence the seizure threshold, that the toxicity of AEDs 
may be influenced by a co-morbid condition and that clinically relevant drug–drug 
interactions can arise from the co-administration of AEDs with drugs used to treat co-morbid 
diseases (Zaccara, 2009). In addition to direct health care costs, future studies need to elicit 
direct non-health care costs of transportation to health care professionals and indirect costs. 
With respect to the latter, attention needs to be paid to calculating the indirect costs of days 
lost to education, costs of reduced ability to carry out normal everyday activities, and the costs 
of productivity loss of patients and of family/friends who care for patients. 
 
Direct health care costs 
Direct non-health 
care costs 
Indirect costs  
of patients and 
carers 
Medication 
Health care 
providers 
Other   
Anti-epileptic drugs 
 
Antidepressants 
 
Antipsychotics 
 
Benzodiazepines 
 
Cardiovascular drugs 
 
Antineoplastic drugs 
 
Antibiotics 
 
Antiretroviral drugs 
 
Interferons 
General 
practitioner 
 
Nurse 
 
Pharmacist 
 
Neurologist 
 
 
Diagnostic tests 
 
Accident and 
Emergency visit 
 
Hospital stay 
 
Surgery 
 
Palliative care 
 
Home health  
care services 
 
Alternative 
medicine 
Transportation  
to health care 
provider 
 
Child care costs 
 
Home 
adaptations 
Absence from 
work 
 
Reduced 
productivity at 
work 
 
Time lost from 
education 
 
Reduced ability 
to carry out 
usual daily 
activities 
Table 1. Items to be considered in cost studies of lacosamide 
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3.4 Cost-effectiveness 
Three economic evaluations used a similar design to determine the cost-effectiveness of 
lacosamide from the health care payer perspective in Sweden, Finland and Belgium (Bolin et 
al., 2010; Simoens et al., 2010; Soini et al., 2009). These studies compared standard AED 
therapy plus lacosamide with standard AED therapy alone in treating partial-onset seizures 
with or without secondary generalization in epilepsy patients from 16 years who are 
uncontrolled on current treatment with at least two AEDs. 
A decision-analytic model simulated the treatment pathway of a hypothetical patient cohort 
over two years. Data about health state probabilities, seizure frequency and utility values 
were taken from the pivotal trials or from the literature. For instance, the models used a 
probability of a seizure reduction of 0.368 and a probability of withdrawal due to non-
response of 0.632 in patients treated with standard AED therapy plus lacosamide. Similarly, 
the probability of a 50% seizure reduction was 0.194 and the probability of withdrawal due 
to non-response was 0.806 in patients treated with standard AED therapy alone. Health care 
costs included costs of drugs, physician visits, laboratory tests, and hospitalization. The two 
consequence measures considered were the number of seizures and quality-adjusted life 
years because AED treatment primarily impacts seizure frequency and health-related 
quality of life. As the models did not take into account adverse events, the costs associated 
with adverse events associated with AED treatment was not considered when calculating 
the cost-effectiveness of lacosamide. Also, the models did not consider mortality. This is 
because the trials 754 and 755 did not report mortality rates in this specific population of 
uncontrolled epileptic patients and because of the limited time period of the models of two 
years (Chung et al., 2010; Halasz et al., 2009). The robustness of results was tested by means 
of deterministic and probabilistic sensitivity analyses. 
The Swedish economic evaluation found that the incremental cost per seizure avoided 
amounted to € 156 and that the incremental cost per quality-adjusted life year gained was € 
27,641 at 24 months (Bolin et al., 2010). If indirect costs of productivity loss would be 
considered, standard therapy plus lacosamide would be more effective and less expensive 
than standard therapy alone. According to the Finnish economic evaluation, standard 
therapy plus lacosamide led to a reduction of 8.92 seizures, an increase of 0.041 quality-
adjusted life years, and a cost increase of € 831 per patient as compared with standard 
therapy alone over a 24-month period (Soini et al., 2009). Using a willingness to pay of € 
30,000 and € 50,000 per quality-adjusted life year, the probability of standard therapy plus 
lacosamide being cost-effective was 74.4% and 87.7%, respectively. The Belgian economic 
evaluation observed that standard therapy plus lacosamide is more effective and less 
expensive than standard therapy alone under the two consequence measures considered 
and under the four time periods considered (6, 12, 18 and 24 months) (Simoens et al., 2010). 
Extensive sensitivity analyses demonstrated that these results were robust to changes in 
input parameters. 
3.5 Budget impact 
In addition to cost-effectiveness, the Finnish study calculated the budget impact of 
lacosamide from the health care payer perspective (Soini et al., 2009). The analysis compared 
the “world with lacosamide” to the “world without lacosamide” and calculated how a 
change in the mix of AEDs used to treat uncontrolled epilepsy would impact drug spending 
during 2008-2012. Data on the number of patients, AED market shares and unit costs were 
taken from Finnish sources. The authors applied the conservative assumption of using 
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generic drug prices in the analysis. It should be noted that this analysis focused on drug 
costs only and did not consider the fact that lacosamide reduces costs of seizure 
management and withdrawal, as demonstrated by the economic evaluations (Bolin et al., 
2010; Simoens et al., 2010; Soini et al., 2009). The results indicated that the expected annual 
drug budget increase due to the introduction of lacosamide would rise to € 232,600 in 2012. 
Expressed as a proportion of the annual epilepsy budget, the introduction of lacosamide 
would increase the budget by 2.23% in 2012. 
4. Discussion 
Insufficient epilepsy treatment in terms of seizure control may have a significant negative 
impact on patients’ quality of life and represents a substantial economic burden for patients 
and society. There is an unmet need for treatment options for uncontrolled patients with 
partial-onset seizures. Lacosamide, a second-generation AED, is indicated for the treatment 
of such patients. This study has drawn on the international literature in order to provide a 
comprehensive review of various aspects of pharmacotherapy with lacosamide (i.e. safety, 
tolerability, efficacy, costs, cost-effectiveness and budget impact). Although the review 
considered both published articles and congress abstracts, the evidence on lacosamide was 
limited and studies suffered from a number of methodological limitations. The evidence, 
limitations and avenues for future research are discussed in the following paragraphs. 
The safety, tolerability and efficacy of lacosamide as an adjunctive therapy in partial-onset 
seizures have been demonstrated across three randomised, placebo-controlled, double-
blind, multicentre trials in over 1,300 adults with epilepsy. Patients receiving lacosamide 
demonstrated a significant reduction in seizure frequency and significantly higher 50% 
response rates in comparison with patients who received placebo. Furthermore, open-label 
extension studies showed that long-term treatment with lacosamide produced a sustained 
efficacy in and was generally well tolerated by patients. 
The existing clinical evidence has investigated the efficacy of lacosamide under ‘ideal 
conditions’ rather than its effectiveness in real-life practice. Also, populations studied in 
clinical trials may not reflect populations observed in clinical practice. There is a need for 
post-marketing surveillance studies that conduct head-to-head comparisons of different 
combinations of AEDs including lacosamide. Although analyses based on cohort studies, 
case-control studies, or before-and-after studies may suffer from a number of biases and do 
not always establish a cause and effect relationship, such studies would provide information 
about the safety, tolerability, and effectiveness of lacosamide in real-life practice.  
Existing economic evaluations have drawn on similar decision-analytic models to 
investigate the cost-effectiveness of lacosamide in three different countries. The evidence 
indicated that in patients who are difficult to treat with currently reimbursed treatment 
alternatives, standard AED therapy plus lacosamide is likely to constitute a cost-effective 
alternative. The budget impact of introducing adjunctive therapy with lacosamide is also 
likely to be limited. Uncertainty surrounds the cost-effectiveness of lacosamide because 
economic evaluations derived efficacy estimates from short-term trial data, thus 
necessitating extrapolation; there are few head-to-head comparisons of the efficacy of AEDs; 
and there are few data on utility values associated with epileptic health states.  
There is a need for more economic evaluations of adjunctive therapy of partial-onset 
seizures with lacosamide. Studies need to be carried out that collect primary long-term data 
on effectiveness and cost-effectiveness of lacosamide as compared to other available AEDs. 
www.intechopen.com
Health Technology Assessment of Lacosamide  
as Adjunctive Therapy for Partial-Onset Epileptic Seizures 
 
211 
Further research needs to assess quality of life, using preference-based measures of 
outcomes that generate appropriate utilities for economic evaluation. 
5. Conclusion 
Because of the complexity of epilepsy diagnosis and management, physicians should be 
presented with a wide choice of therapeutic options in order to individualize AED treatment 
to each patient. In light of the available evidence, lacosamide needs to be considered as a 
safe, efficacious and cost-effective option as adjunctive therapy for patients with partial-
onset epilepsy with or without secondary generalization who are uncontrolled having 
previously used at least three AEDs. However, these results need to be validated by studies 
that explore the impact of lacosamide in real-life clinical practice.  
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